SCHEMBL6180967

SCHEMBL6180967

CC(C)C[C@H](Nc1nc(-c2ccc(N3CCOCC3)cc2)cs1)C(=O)NCC#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 14/20 0.57
CTSL P07711 13/20 0.57
CTSB P07858 12/20 0.57
CTSK P43235 9/20 0.57
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP1B1 Q16678 1/20 0.46
ALOX5 P09917 1/20 0.46
LMNA P02545 1/20 0.46
BMPR1B O00238 1/20 0.46
PLK4 O00444 1/20 0.46
CIT O14578 1/20 0.46
GAK O14976 1/20 0.46
OPA1 O60313 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
STK16 O75716 1/20 0.46
PRKD3 O94806 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182674 0.94 CTSL (0.59) CTSSCTSLCTSBCTSK
SCHEMBL6180116 0.85 CTSK (0.56) CTSSCTSLCTSBCTSKSTAT3
SCHEMBL6184351 0.83 CTSL (0.54) CTSSCTSLCTSBCTSKROCK2
SCHEMBL6182190 0.82 CTSL (0.62) CTSSCTSLCTSBCTSK
SCHEMBL6182195 0.82 CTSL (0.62) CTSSCTSLCTSBCTSK
SCHEMBL6182508 0.80 LMNA (0.58) CTSSCTSLCTSBCTSKLMNA
SCHEMBL6183599 0.79 CTSL (0.55) CTSSCTSLCTSBCTSKLMNA
SCHEMBL4698735 0.78 CTSS (0.55) CTSSCTSLCTSBCTSK
SCHEMBL6183695 0.77 CTSK (0.75) CTSSCTSLCTSBCTSK
SCHEMBL6183760 0.77 CTSL (0.49) CTSSCTSLCTSBCTSKHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001068645-A2 N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-09-20 WO claimed
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSS 10/4885CTSL 14/4885CTSB 11/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSS 10/4885CTSL 14/4885CTSB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.